Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Status:
Completed
Trial end date:
2021-01-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with
placebo on overall survival in subjects with advanced hepatocellular carcinoma who have
received prior sorafenib.